Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On the crossroads of interdisciplinary medicine in amyloidosis - study protocol for a single-center interdisciplinary registry study.

PloS one·2026
Same author

Photon-counting CT vs V/Q SPECT for lobar perfusion quantification in chronic thromboembolic pulmonary hypertension.

European radiology·2026
Same author

Myocardial Perfusion SPECT 2024 in Germany: Results of the 10th Survey.

Nuklearmedizin. Nuclear medicine·2025
Same author

The German Cancer Consortium (DKTK) multi-center prospective phase 1/2 <sup>68</sup>Ga-PSMA-11 PET-imaging trial in newly-diagnosed high-risk prostate cancer: Safety and diagnostic accuracy compared to histopathology and their impact on patient management.

European journal of nuclear medicine and molecular imaging·2025
Same author

Confounding by indication in observational studies investigating glucocorticoid-associated adverse events in patients with rheumatoid arthritis: a systematic literature review including an assessment of E-values.

Annals of the rheumatic diseases·2025
Same author

Medical Expert Knowledge Meets AI to Enhance Symptom Checker Performance for Rare Disease Identification in Fabry Disease: Mixed Methods Study.

JMIR AI·2025

Related Experiment Video

Updated: Jul 9, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.2K

Mycophenolate mofetil in giant cell arteritis.

Anne Pankow1,2, Sena Sinno2, Thorsten Derlin3

  • 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.

Frontiers in Medicine
|November 29, 2023
PubMed
Summary
This summary is machine-generated.

Mycophenolate mofetil (MMF) effectively induces remission in patients with giant cell arteritis (GCA). This lymphocyte-specific immunosuppressive therapy demonstrated reduced CRP levels and sustained disease control in a case series.

Keywords:
Mycophenolate mofetilcase seriesgiant cell arteritisimagingvasculitis

More Related Videos

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
06:57

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

2.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Related Experiment Videos

Last Updated: Jul 9, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.2K
Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis
06:57

Author Spotlight: Adjuvant Activity of Mycobacterium paratuberculosis in Enhancing the Immunogenicity of Autoantigens During Experimental Autoimmune Encephalomyelitis

Published on: May 12, 2023

2.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Area of Science:

  • Rheumatology
  • Immunology
  • Internal Medicine

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis impacting large arteries, with abnormal lymphocyte function implicated in its pathogenesis.
  • Mycophenolate mofetil (MMF) is a lymphocyte-specific immunosuppressant targeting inosine monophosphate dehydrogenase.

Purpose of the Study:

  • To evaluate the efficacy of Mycophenolate mofetil (MMF) in achieving disease remission for patients diagnosed with Giant Cell Arteritis (GCA).

Main Methods:

  • A retrospective case series of seven GCA patients treated with MMF between 2010 and 2023.
  • Diagnosis confirmation via duplex sonography, 18F-FDG PET, MRI, and/or biopsy.
  • Primary endpoints included recurrence rates, CRP levels at 3-6 and 6-12 months, and remission duration.

Main Results:

  • All patients exhibited inflammatory activity in arterial vessels confirmed by imaging or biopsy.
  • C-reactive protein (CRP) levels significantly decreased at 3-6 and 6-9 months post-MMF initiation.
  • Complete disease remission was achieved in all seven patients during the study period.

Conclusions:

  • Mycophenolate mofetil (MMF) shows promise as an effective treatment for controlling disease activity in Giant Cell Arteritis (GCA).
  • Further investigation through randomized controlled trials is warranted to confirm these findings.